4//SEC Filing
Domzalski David 4
Accession 0001415889-25-015382
CIK 0001566044other
Filed
Jun 2, 8:00 PM ET
Accepted
Jun 3, 4:15 PM ET
Size
5.6 KB
Accession
0001415889-25-015382
Insider Transaction Report
Form 4
Domzalski David
DirectorPRESIDENT AND CEO
Transactions
- Award
Common Stock
2025-06-02$0.81/sh+8,681$7,032→ 454,244 total
Footnotes (1)
- [F1]These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2024 and ending on May 31, 2025 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on May 30, 2025 (the last trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.
Documents
Issuer
VYNE Therapeutics Inc.
CIK 0001566044
Entity typeother
Related Parties
1- filerCIK 0001727794
Filing Metadata
- Form type
- 4
- Filed
- Jun 2, 8:00 PM ET
- Accepted
- Jun 3, 4:15 PM ET
- Size
- 5.6 KB